[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2961420T3 - Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom - Google Patents

Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom Download PDF

Info

Publication number
DK2961420T3
DK2961420T3 DK14756991.7T DK14756991T DK2961420T3 DK 2961420 T3 DK2961420 T3 DK 2961420T3 DK 14756991 T DK14756991 T DK 14756991T DK 2961420 T3 DK2961420 T3 DK 2961420T3
Authority
DK
Denmark
Prior art keywords
prevention
compositions
treatment
methods
barth syndrome
Prior art date
Application number
DK14756991.7T
Other languages
English (en)
Inventor
D Travis Wilson
Mark Bamberger
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Application granted granted Critical
Publication of DK2961420T3 publication Critical patent/DK2961420T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK14756991.7T 2013-03-01 2014-02-28 Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom DK2961420T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361771642P 2013-03-01 2013-03-01
US201361771534P 2013-03-01 2013-03-01
US201361839753P 2013-06-26 2013-06-26
PCT/US2014/019622 WO2014134554A1 (en) 2013-03-01 2014-02-28 Methods and compositions for the prevention or treatment of barth syndrome

Publications (1)

Publication Number Publication Date
DK2961420T3 true DK2961420T3 (da) 2019-10-07

Family

ID=51428869

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14756991.7T DK2961420T3 (da) 2013-03-01 2014-02-28 Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom

Country Status (9)

Country Link
US (5) US9687519B2 (da)
EP (2) EP3626252A1 (da)
JP (4) JP6518197B2 (da)
CN (3) CN115990242A (da)
CA (1) CA2916880C (da)
DK (1) DK2961420T3 (da)
ES (1) ES2750258T3 (da)
HU (1) HUE046924T2 (da)
WO (1) WO2014134554A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2014134554A1 (en) * 2013-03-01 2014-09-04 Stealth Peptides International, Inc. Methods and compositions for the prevention or treatment of barth syndrome
EP2961378B1 (en) 2013-03-01 2019-10-23 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
US10086040B2 (en) 2014-12-12 2018-10-02 University Of Washington Methods for treating and preventing cardiomyopathy with a fusion protein of tafazzin and a cellular permeability peptide
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
CN110914287A (zh) 2017-04-05 2020-03-24 隐形生物治疗公司 Boc-d-arg-dmt-lys-(boc)-phe-nh2的结晶盐形式
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
KR20210093958A (ko) * 2018-12-18 2021-07-28 스텔스 바이오테라퓨틱스 코포레이션 미토콘드리아 질환을 표적으로 하는 유사체

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CA2495021A1 (en) 2001-08-06 2003-07-03 Vanderbilt University System and methods for measuring at least one metabolic rate of a plurality of cells
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
SI1599216T1 (sl) 2003-02-04 2014-02-28 Cornell Research Foundation, Inc. Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
AU2004210013A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CN1938042B (zh) 2004-01-23 2010-06-02 科内尔研究基金会 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
CA2649720A1 (en) * 2006-04-18 2007-10-25 Tim Stewart Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
US9603872B2 (en) 2007-05-02 2017-03-28 The McLeon Hospital Corporation Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
US20090143279A1 (en) 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
WO2009149307A2 (en) 2008-06-04 2009-12-10 San Diego State University Research Foundation Compositions and methods for restoring mitochondrial electron transfer function
CN104231070B (zh) 2008-08-07 2017-09-01 益普生制药股份有限公司 N‑端修饰的葡萄糖依赖性促胰岛素多肽（gip）类似物
CN103933542A (zh) 2009-03-20 2014-07-23 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
US20120122957A1 (en) 2009-04-17 2012-05-17 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
US20120046363A1 (en) 2009-05-11 2012-02-23 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
EP3427746A1 (en) 2009-08-12 2019-01-16 Cornell University Methods for preventing or treating metabolic syndrome
EP2470191B1 (en) * 2009-08-24 2014-05-07 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell METHODS FOR PREVENTING OR TREATING HEART FAILURE
CN102791280A (zh) * 2009-12-31 2012-11-21 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
CA2797644A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
US20130040901A1 (en) 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
US8697657B2 (en) 2010-03-15 2014-04-15 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP2566880A4 (en) 2010-05-03 2014-10-08 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
US20140031432A1 (en) 2010-08-06 2014-01-30 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
WO2012019029A2 (en) 2010-08-06 2012-02-09 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with naphthoquinones
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
JP2014520246A (ja) * 2011-03-24 2014-08-21 コーネル ユニヴァーシティー 芳香族カチオン性ペプチド及びその使用
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
CN104114181B (zh) 2011-10-17 2017-06-09 康奈尔大学 芳香族阳离子肽及其用途
AU2012325723A1 (en) * 2011-10-21 2014-05-15 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules
AU2013222423A1 (en) 2012-02-22 2014-09-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CN104203262A (zh) * 2012-02-23 2014-12-10 康奈尔大学 芳香族阳离子肽及其用途
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
BR112015009072A2 (pt) * 2012-10-22 2017-07-04 Henry Ford Health Systems métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma
EP2961378B1 (en) 2013-03-01 2019-10-23 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
WO2014134554A1 (en) 2013-03-01 2014-09-04 Stealth Peptides International, Inc. Methods and compositions for the prevention or treatment of barth syndrome
WO2014209905A2 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
US11083771B2 (en) 2021-08-10
JP2019147815A (ja) 2019-09-05
CN115990242A (zh) 2023-04-21
CN105407906A (zh) 2016-03-16
US20180147251A1 (en) 2018-05-31
JP2022116008A (ja) 2022-08-09
US20160228487A1 (en) 2016-08-11
JP6518197B2 (ja) 2019-05-22
US20200345803A1 (en) 2020-11-05
HUE046924T2 (hu) 2020-03-30
JP7381652B2 (ja) 2023-11-15
CA2916880A1 (en) 2014-09-04
US11771734B2 (en) 2023-10-03
EP3626252A1 (en) 2020-03-25
CN115990241A (zh) 2023-04-21
JP6918046B2 (ja) 2021-08-11
ES2750258T3 (es) 2020-03-25
JP7072692B2 (ja) 2022-05-20
JP2021098704A (ja) 2021-07-01
JP2016511259A (ja) 2016-04-14
US11083772B2 (en) 2021-08-10
CA2916880C (en) 2021-02-09
EP2961420A1 (en) 2016-01-06
US20240156892A1 (en) 2024-05-16
WO2014134554A1 (en) 2014-09-04
US9687519B2 (en) 2017-06-27
EP2961420A4 (en) 2016-08-17
US20210401923A1 (en) 2021-12-30
EP2961420B1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
DK3364993T3 (da) Fremgangsmåder til behandling af angelman syndrom
DK2961420T3 (da) Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK2906698T3 (da) Fremgangsmåde til behandling af alports syndrom
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3693158T3 (da) Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2854850T3 (da) Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3033081T3 (da) Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3217963T3 (da) Fremgangsmåder til behandling af individer med prader-willis syndrom eller smith-magenis syndrom
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase